- Immutep (ASX:IMM) announces new biomarker data from its phase II TACTI-002 trial for patients with previously untreated unresectable or metastatic NSCLC
- Data from blood samples reveals unique immune system stimulation when using efti in combination with pembrolizumab
- The biomarker data is to be presented at the SITC 38th annual meeting
- IMM shares are up five per cent, trading at 31.5 cents at 11:28 am AEDT
Immutep (ASX:IMM) has announced new biomarker data from its phase II TACTI-002 trial for patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC).
New biomarker data from blood samples has revealed unique immune system stimulation when using eftilagimod alpha (efti) in combination with pembrolizumab, which is a first-line treatment for NSCLC.
“Immunomonitoring of blood cells is of prime importance when one would like to understand the effect of a systemic immunostimulant injected subcutaneously like efti is,” IMM CEO Frederic Triebel said.
The biomarker data will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th annual meeting, where the company showcased positive overall survival results of its clinical trial.
“Importantly, the pharmacodynamic data from efti in combination with pembrolizumab is associated with the 35.5-month median overall survival in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1 per cent) that we recently reported at ESMO 2023.”
IMM shares were up five per cent, trading at 31.5 cents at 11:28 am AEDT.